Clinical trial · no report yet · Phase 3
NCT03742297
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
- NCT03742297 ↗
- Active not recruiting
- PETHEMA Foundation
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 19 | |
| YouTube | 7 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- Induction Therapy With Bortezomib-melphalan and Prednisone (VMP) Followed by Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab, 18 Cycles, Followed by Consolidation and Maintenance Therapy With Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Lenalidomide.; Carfilzomib; Bortezomib; Daratumumab; Dexamethasone; Prednisone; Melphalan
- Arms
- VMP x 9 + Lenalidomida-dexamethasone x 9 · Active comparator
- Carfilzomib-lenalidomida-dexamethasone regimen · Experimental
- Carfilzomib-lenalidomida-dexamethason with daratumumab · Experimental
- Enrollment
- 462
- Primary outcomes
- Efficacy in terms of numbers of compleat responses
- Sponsor
- PETHEMA Foundation
- Start
- Oct 22, 2018
- Primary completion
- Jul 2023 (estimated)
- Results posted
- No
- Registry record
- NCT03742297 · updated Sep 14, 2022
Publications
linked from the registry- Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosinol L, Montes YG, Bargay J, Garcia MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzon S, Montero FC, Cabanas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasus AIT, Delgado-Beltran MP, Prieto E, Lahuerta JJ, Blade J, San-Miguel J. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial. Lancet Haematol. 2025 Aug;12(8):e588-e598. doi: 10.1016/S2352-3026(25)00143-7. PubMed 40769684